Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. - Wikidata - wikimedia - TriplyDB

Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

http://www.wikidata.org/entity/Q37534910

about

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer Everolimus in the Treatment of Metastatic Breast Cancer Ten things you should know about protein kinases: IUPHAR Review 14 Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Safety of mTOR inhibitors in breast cancer.Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.ABC4 Consensus: Assessment by a German Group of Experts Low serum gastrin associated with ER breast cancer development via inactivation of CCKBR/ERK/P65 signaling

P2860

Q26741153-EB355199-EA66-4450-94BF-0BBEC776DF1A Q26770482-261420CF-AA2E-4D5C-BC4E-AA18D74ED2CC Q26775361-8553AB3C-8B54-4A3F-8C4B-F48CB9645637 Q26777734-CA72956B-3D99-42B6-B17F-4B4D65CD6C96 Q26784920-42B6E565-871A-4FED-911D-5C4969E9FC2A Q26849417-92CF53D9-948A-4D0D-9261-D2B933B4EEDA Q28076777-963DEDE8-C308-47C6-9EE2-07145B4DE779 Q28085004-F52628C4-DBFE-47F3-8D4D-23CA9B7A7749 Q33727284-40A1E566-A06E-4EF5-AA39-BF5F72BB4619 Q34352887-0DB65266-05D0-432C-94DB-F1A44F4B23A5 Q35675851-D7A924D2-EDC2-4799-8F33-49091F1E54CA Q35826810-F5C0E7B6-D621-4F1D-BCFC-C24EBCF2AB1D Q36078905-0058C1C5-EAA0-4506-96EC-8E42C3661632 Q36355880-1567FDDA-069D-4B54-953D-CA7F1F9B5401 Q38250444-D8DF7DCF-E19B-45CD-B587-E7C56285864F Q38502890-EB3D1DAF-0D50-48B3-BB04-C7EA16DC4841 Q38690803-D0125B68-95BF-446A-A295-3FB096ECED96 Q38841039-5444B49D-8486-4B45-856F-13DCF6B5A5A4 Q38852355-A3F8A36B-9CAD-444E-AFDA-1F9A6E41853B Q39172983-35F8E5D6-0345-4F29-9D69-4947548120BE Q40126367-482449D0-E3C4-47EB-A6B9-0FD25DC7E915 Q40814112-081B0E1B-F322-4A3E-8F4D-343BD29A8F9C Q46605325-539EBE65-5DB3-4131-88B8-72D40D768F17 Q47825566-83383388-F1D3-44CC-8079-28A7B46E0252 Q48342762-7F8176DC-3CCE-46D1-82D9-C3619136366A Q49970203-9C644568-0A48-4FA2-80CD-92411BFB1675 Q52642671-D43C1B8E-AE9D-41A9-87B2-11731560EA38 Q55339569-D9F8D7F1-FC8F-4F67-A91D-6EEC8B644ECD Q55346396-8BE58482-A94F-48C0-8A8C-D64B2CFB797F Q56968314-AD50A98C-8C7A-49C7-AC1A-5D01A6BE0E8F Q58774122-6A2EBA05-DBA5-4108-87C2-831DDAA92E56

P2860

Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

http://www.wikidata.org/entity/Q37534910

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@en

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@nl

type

label

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@en

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@nl

prefLabel

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@en

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@nl

P1433

Q37534910-67DC3469-C4E5-4330-9AD2-1F4F3D92B14E

P1476

Q37534910-E2E5687C-5CA9-4D75-B7F8-52F6D94B0687

P2093

Q37534910-0623B055-A170-41BA-AFAE-C5BE0506A0AD

Q37534910-109F016B-DFB1-4725-8036-53F5BEFF5980

Q37534910-2F215BC7-D16F-4C27-BC52-CA1782F7679A

Q37534910-35B83FE2-6169-4511-9383-DCA501E8DED3

Q37534910-3C36513A-ED6F-47AE-A3E7-30A3CD7FA20A

Q37534910-8DFAF995-95B9-4B4A-B6FA-7A338263DCB0

Q37534910-9CC1BE4C-8460-44C7-9B82-26A88A322563

Q37534910-A7CC75D1-7490-4B03-B74E-2DB1D4A46B30

Q37534910-B1722D7C-38B6-4141-B787-C9DC2FD301FB

Q37534910-B51FD9F1-02A1-4DC2-8076-D2148D5B2B5C

P2860

Q37534910-09D9153D-02EF-49EA-8FBD-F8CA63373B03

Q37534910-0DEFFB2D-B658-46F6-8132-669C39716223

Q37534910-0EB28E26-46FF-48AE-9D17-7658EFB1613C

Q37534910-1224FE20-64C9-40E2-A641-4777471A8B26

Q37534910-19955B99-7EBD-4813-8AD7-E9CA60B2A999

Q37534910-26C8A675-ACA8-4F98-A0DA-E084CB0D7B4C

Q37534910-2EB3CF96-D872-4D62-83AA-7AE91271B34B

Q37534910-2F39B60D-804A-42E6-BF49-8B52DA566167

Q37534910-2F9A5F12-BB14-4ECD-A2FA-4CC93147858C

Q37534910-38E9F82A-9A99-49E7-B319-9245A0578855

P2888

Q37534910-0494373A-A9CF-4378-8526-F061F6E7BDD2

P304

Q37534910-73B69213-B3EA-4E8A-B379-862EE9FFFDBC

P31

Q37534910-37C1116C-FB44-4CF3-A646-18F35C9E5519

P356

Q37534910-EA06BDEE-2DFA-4E64-9F0A-DFA204472733

P407

Q37534910-A03DB632-2280-4FF6-AEE8-0C0739A10A8D

P433

Q37534910-5B893B58-CB79-441E-97D2-D28A8C667B19

P478

Q37534910-3BBF77B9-7519-4FD3-BE0B-3AF905C21F42

P577

Q37534910-32B6467F-23C8-44A9-99E8-7E66CAE9734E

P5875

Q37534910-ECD2D271-E50D-473C-B848-4C8BDDE62F50

P698

Q37534910-B7B5F093-B9E7-4B04-BD57-0D00B0D8589E

P932

Q37534910-48F1BE39-853D-4C14-9310-830DA6BDF1AB

P356

S10549-013-2814-5

P1433

Breast Cancer Research and Treatment

P1476

Everolimus plus exemestane as ...... ced breast cancer in BOLERO-2.

@en

P2093

Barbara Pistilli

http://www.w3.org/2001/XMLSchema#string

Bohuslav Melichar

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

Fabienne Lebrun

http://www.w3.org/2001/XMLSchema#string

Francois Ringeisen

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Ines Deleu

http://www.w3.org/2001/XMLSchema#string

J Thaddeus Beck

http://www.w3.org/2001/XMLSchema#string

Lowell Hart

http://www.w3.org/2001/XMLSchema#string

P2860

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

1st International consensus guidelines for advanced breast cancer (ABC 1).

The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.

P2888

s10549-013-2814-5

P304

459-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2814-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259449529

http://www.w3.org/2001/XMLSchema#string

P698

24362951

http://www.w3.org/2001/XMLSchema#string

P932

3907668

http://www.w3.org/2001/XMLSchema#string